Skip to main content
Monday, November 16, 2026Nov 16

Spiraling drug costs prompt call for major Medicare changes

FILE - In this June 14, 2011 file photo, various prescription drugs on the automated pharmacy assembly line at Medco Health Solutions in Willingboro, N.J. Calling the rising cost of drugs “unsustainable,” congressional advisers Wednesday, June 15, 2016, recommended major changes to Medicare’s popular outpatient prescription program, now 10 years old.  (AP Photo/Matt Rourke, File)
FILE - In this June 14, 2011 file photo, various prescription drugs on the automated pharmacy assembly line at Medco Health Solutions in Willingboro, N.J. Calling the rising cost of drugs “unsustainable,” congressional advisers Wednesday, June 15, 2016, recommended major changes to Medicare’s popular outpatient prescription program, now 10 years old. (AP Photo/Matt Rourke, File)

WASHINGTON (AP) – Calling the rising cost of drugs “unsustainable,” congressional advisers on Wednesday recommended major changes to Medicare’s popular outpatient prescription program, now 10 years old.

The proposal from the nonpartisan Medicare Payment Advisory Commission, or MedPAC, steers clear of calling for the government to negotiate drug prices directly, an option both presidential candidates advocate. For beneficiaries, the plan is a mixed bag. All seniors would get better protection from extremely high costs, but some may have to spend more.

The recommendations are unlikely to gain traction in Congress during an election year, but they will get a serious look from staff experts on key House and Senate committees overseeing Medicare.

MedPAC is a congressional agency charged with making regular recommendations on Medicare, the government’s premier health insurance program, with about 57 million elderly and disabled beneficiaries. Echoing widespread concerns about drug costs, MedPAC said spending for Medicare’s prescription program grew by nearly 60 percent from 2007 through 2014, from $46 billion to $73 billion.

That was driven by spending on high-cost beneficiaries who tend to use the most expensive medications, such as the recent breakthrough cures for hepatitis C infection. Congress should re-examine the program’s design “to better ensure financial sustainability,” the commission said.